Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Adverse events Any untoward medical occurrence regarding medications · people with neurosyphilis
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with severe Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · people with Alzheimer's disease
Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: sepsis (as reported by study authors at end of study · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes participants with acute…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: sepsis (as reported by study authors at end of study · critically ill adults admitted to the ICU for trauma, emergency, or post‐surgical care; population excludes participants with acute…
Enteral may leads to lower adverse events: sepsis (as reported by study authors at end of study compared with parenteral nutrition (low certainty).
1 finding from 1 review
Adverse events (total adverse events) (oestrogen cream vs non‐hormonal lubricant gel) · postmenopausal women with vaginal atrophy
Oestrogen tablets showed no clear difference in adverse events (total adverse events) (oestrogen tablets vs placebo) compared with other regimens (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events None of the included studies evaluated adverse events · patients with acute low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events None of the included studies evaluated adverse events · patients with acute LBP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events None of the included studies evaluated adverse events · patients with acute low back pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · Apathy in people with mild‐to‐moderate Alzheimer's disease
Rivastigmine probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects dystonia ‐ short term compared with ANY ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
1 finding from 1 review
Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon alpha‐2a showed no clear difference in adverse events leading to treatment discontinuation Number of events compared with peginterferon alpha‐2b (low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with ≥ 1 serious adverse events during treatment · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events considered non‐serious (penicillin versus doxycycline) · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious (penicillin versus doxycycline) compared with other antibiotics (very low certainty).
1 finding from 1 review
Participants with adverse events ‐ any local symptom Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine probably leads to higher participants with adverse events ‐ any local symptomClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review